Elias Chandran

9PUBLICATIONS
26CO-AUTHORS
Molecular targetsChemotherapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 23, 2025
A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationale.

Andre R Kydd, Elias Chandran, Nicholas I Simon

|May 27, 2025
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale.

Elias B A Chandran, Saad Atiq, Nicholas Simon

|Mar 21, 2025
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationale.

Nicholas Simon, Elias Chandran, Saad Atiq

|Aug 01, 2024
Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis.

Elias B A Chandran, Giovanni Maria Iannantuono, Saad O Atiq

|Jul 02, 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Andrea B Apolo, Daniel M Girardi, Scot A Niglio

|Apr 27, 2023
Emerging treatment options for prostate cancer.

Mohammad Atiq, Elias Chandran, Fatima Karzai

Pageof 2